In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Akebia Therapeutics Inc. (NASDAQ:AKBA) reported that Satter Muneer A has picked up 3,054,542 of common stock as of 2017-07-14.
The acquisition brings the aggregate amount owned by Satter Muneer A to a total of 3,054,542 representing a 6.48% stake in the company.
For those not familiar with the company, Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company’s vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
A glance at Akebia Therapeutics Inc. (NASDAQ:AKBA)’s key stats reveals a current market capitalization of $633.79 Million based on $46.49 Million shares outstanding and a price at last close of $13.86 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-07-05, Satter picked up 1,034,482 at a purchase price of $14.50. This brings their total holding to 3,037,042 as of the date of the filing.
On the sell side, the most recent transaction saw Dahan unload 1,399 shares at a sale price of $14.26. This brings their total holding to 107,224.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Akebia Therapeutics Inc. (NASDAQ:AKBA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.